同: バルビツレート療法

WordNet

(medicine) the act of caring for someone (as by medication or remedial training etc.); "the quarterback is undergoing treatment for a knee injury"; "he tried every treatment the doctors suggested"; "heat therapy gave the best relief"
organic compound having powerful soporific effect; overdose can be fatal

PrepTutorEJDIC

(病気の)治療,療法 / =psychotherapy
バルビツル酸塩(睡眠薬・鎮通剤用)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における頭蓋内圧亢進の評価およびマネージメント evaluation and management of elevated intracranial pressure in adults
2. 成人における片頭痛の急性期治療 acute treatment of migraine in adults
3. 成人における急性肝不全：マネージメントおよび予後 acute liver failure in adults management and prognosis
4. 成人におけるてんかん重積状態 status epilepticus in adults
5. 新生児痙攣の治療 treatment of neonatal seizures

English Journal

Anti-epileptic drugs and hormonal treatments.

Johnston CA1, Crawford PM.Author information 1The York Hospital, Wigginton Road, York, YO31 8HE, UK, clare.johnston@york.nhs.uk.AbstractOPINION STATEMENT: Epilepsy and the medications used in its treatment are known to affect the menstrual cycle, aspects of contraception, and bone health in women. Adolescence is an important time to review the diagnosis of both epilepsy and the epilepsy syndrome because of the implications and decisions, which should be made regarding antiepileptic drug (AED) treatment. In girls, once they are on AED therapy, seizure free, and driving, it becomes difficult to change therapy because of the risk of breakthrough seizures and the fact that the new AED may not be as effective as the first. So a treatment choice made in adolescence is often life-long. Therefore, women need to be started on an AED that currently appears to be the most suitable for their seizure type, has a low teratogenic risk, and hopefully does not interact with contraception. There are no contraindications to the use of non-hormonal methods of contraception in women with epilepsy. Nonenzyme-inducing AEDs (valproate, benzodiazepines, ethosuximide, levetiracetam, tiagabine, and zonisamide) do not show any interactions with the combined oral contraceptive. There are interactions between the combined oral contraceptive and hepatic microsomal-inducing AEDs (phenytoin, barbiturates, carbamazepine, topiramate [dosages >200 mg/day], oxcarbazepine, eslicarbazepine and perampanel [dosages >12 mg/day]) and lamotrigine. Women taking enzyme inducing AEDs should be encouraged to use a method of contraception that is unaffected by their epilepsy medication. Interactions between AEDs and other hormonal therapies are less well studied. Studies have suggested that women with epilepsy are at increased risk of fractures, osteoporosis, and osteomalacia. No studies have been undertaken looking at preventative therapies for these comorbidities. This article will concentrate on current contraceptive treatment options in patients taking AEDs.
Current treatment options in neurology.Curr Treat Options Neurol.2014 May;16(5):288. doi: 10.1007/s11940-014-0288-3.
OPINION STATEMENT: Epilepsy and the medications used in its treatment are known to affect the menstrual cycle, aspects of contraception, and bone health in women. Adolescence is an important time to review the diagnosis of both epilepsy and the epilepsy syndrome because of the implications and decis
PMID 24682679

A diaCEST MRI approach for monitoring liposomal accumulation in tumors.

Chan KW1, Yu T2, Qiao Y3, Liu Q3, Yang M2, Patel H4, Liu G5, Kinzler KW3, Vogelstein B3, Bulte JW6, van Zijl PC5, Hanes J7, Zhou S3, McMahon MT8.Author information 1Russell H. Morgan Department of Radiology and Radiological Sciences, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore 21287, USA; F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore 21205, USA; Center for Nanomedicine, The Johns Hopkins University School of Medicine, Baltimore 21287, USA; Cellular Imaging Section and Vascular Biology Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore 21205, USA.2Center for Nanomedicine, The Johns Hopkins University School of Medicine, Baltimore 21287, USA; Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore 21205, USA.3The Ludwig Center and Howard Hughes Medical Institute at the Hopkins-Kimmel Comprehensive Cancer Center, Baltimore 21287, USA.4Center for Nanomedicine, The Johns Hopkins University School of Medicine, Baltimore 21287, USA.5Russell H. Morgan Department of Radiology and Radiological Sciences, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore 21287, USA; F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore 21205, USA.6Russell H. Morgan Department of Radiology and Radiological Sciences, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore 21287, USA; F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore 21205, USA; Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore 21205, USA; Cellular Imaging Section and Vascular Biology Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore 21205, USA.7Center for Nanomedicine, The Johns Hopkins University School of Medicine, Baltimore 21287, USA; Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore 21205, USA; Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore 21287, USA.8Russell H. Morgan Department of Radiology and Radiological Sciences, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore 21287, USA; F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore 21205, USA; Center for Nanomedicine, The Johns Hopkins University School of Medicine, Baltimore 21287, USA. Electronic address: mtmcmaho@gmail.com.AbstractNanocarrier-based chemotherapy allows preferential delivery of therapeutics to tumors and has been found to improve the efficacy of cancer treatment. However, difficulties in tracking nanocarriers and evaluating their pharmacological fates in patients have limited judicious selection of patients to those who might most benefit from nanotherapeutics. To enable the monitoring of nanocarriers in vivo, we developed MRI-traceable diamagnetic Chemical Exchange Saturation Transfer (diaCEST) liposomes. The diaCEST liposomes were based on the clinical formulation of liposomal doxorubicin (i.e. DOXIL®) and were loaded with barbituric acid (BA), a small, organic, biocompatible diaCEST contrast agent. The optimized diaCEST liposomal formulation with a BA-to-lipid ratio of 25% exhibited 30% contrast enhancement at B1=4.7μT in vitro. The contrast was stable, with ~80% of the initial CEST signal sustained over 8h in vitro. We used the diaCEST liposomes to monitor the response to tumor necrosis factor-alpha (TNF-α), an agent in clinical trials that increases vascular permeability and uptake of nanocarriers into tumors. After systemic administration of diaCEST liposomes to mice bearing CT26 tumors, we found an average diaCEST contrast at the BA frequency (5ppm) of 0.4% at B1=4.7μT while if TNF-α was co-administered the contrast increased to 1.5%. This novel approach provides a non-radioactive, non-metallic, biocompatible, semi-quantitative, and clinically translatable approach to evaluate the tumor targeting of stealth liposomes in vivo, which may enable personalized nanomedicine.
Journal of controlled release : official journal of the Controlled Release Society.J Control Release.2014 Apr 28;180:51-9. doi: 10.1016/j.jconrel.2014.02.005. Epub 2014 Feb 15.
Nanocarrier-based chemotherapy allows preferential delivery of therapeutics to tumors and has been found to improve the efficacy of cancer treatment. However, difficulties in tracking nanocarriers and evaluating their pharmacological fates in patients have limited judicious selection of patients to
PMID 24548481

Decompressive craniectomy or medical management for refractory intracranial hypertension: An AAST-MIT propensity score analysis.

Nirula R1, Millar D, Greene T, McFadden M, Shah L, Scalea TM, Stein DM, Magnotti LJ, Jurkovich GJ, Vercruysse G, Demetriades D, Scherer LA, Peitzman A, Sperry J, Beauchamp K, Bell S, Feiz-Erfan I, O'Neill P, Coimbra R.Author information 1From the University of Utah (R.N., D.M., T.G., M.M., L.S.), Salt Lake City, Utah; University of Maryland Medical Center (T.M.S., D.M.S.), Baltimore, Maryland; University of Tennessee (L.J.M.), Memphis, Tennessee; University of Washington (G.J.J.), Seattle, Washington; Emory University (G.V.), Atlanta, Georgia; University of Southern California-Los Angles County Medical Center (D.D.), Los Angeles; University of California Davis (L.A.S.), Sacramento; and University of California, San Diego (R.C.), San Diego, California; University of Pittsburgh Medical Center (A.P., J.S.), Pittsburgh, Pennsylvania; University of Colorado (K.B., S.B.), Denver Health, Denver, Colorado; and Maricopa Integrated Health Systems (IF-E, P.O.), Phoenix, Arizona.AbstractBACKGROUND: Moderate/severe traumatic brain injury (TBI) management involves minimizing cerebral edema to maintain brain oxygen delivery. While medical therapy (MT) consisting of diuresis, hyperosmolar therapy, ventriculostomy, and barbiturate coma is the standard of care, decompressive craniectomy (DC) for refractory intracranial hypertension (ICH) has gained renewed interest. Since TBI treatment guidelines consider DC a second-tier intervention after MT failure, we sought to determine if early DC (<48 hours) was associated with improved survival in patients with refractory ICH.
The journal of trauma and acute care surgery.J Trauma Acute Care Surg.2014 Apr;76(4):944-55. doi: 10.1097/TA.0000000000000194.
BACKGROUND: Moderate/severe traumatic brain injury (TBI) management involves minimizing cerebral edema to maintain brain oxygen delivery. While medical therapy (MT) consisting of diuresis, hyperosmolar therapy, ventriculostomy, and barbiturate coma is the standard of care, decompressive craniectomy
PMID 24662856

Japanese Journal

軽度脳低温及びバルビツレート療法が有効であった重症硬膜下血腫の一例

上田宣夫,林勝知,森茂,三鴨肇,勝木竜介,寺島圭一,種村衣里子
蘇生 29(2), 103-106, 2010-06-25
NAID 10027716234

重症頭部外傷の治療 : 過去10年間で何が変わったか

川又達朗,片山容一
脳神経外科ジャーナル 15(7), 491-497, 2006-07-20
治療ガイドラインの制定,診療報酬の包括化,臨床研修の必修化など,診療内容に変化を与えるような制度上の変革が起こっている.これらが重症頭部外傷の治療に,この10年間でどのような変化をもたらしたかを調査した.脳低温療法,ステロイド投与,バルビツレート療法,過換気療法などの実施率は低下し,高浸透圧利尿剤投与の実施率が増加している.持続頭蓋内圧測定の実施率は,最も大きな減少を示した.医療収支の検討では,「 …
NAID 110004740356

High-risk症例に対する頸動脈内膜剥離術(CEA)の要点(<特集>頸部頸動脈病変の治療)

山根冠児,島健,西田正博,畠山尚志,三原千恵,石野信輔,豊田章宏,平松和嗣久,真辺和文,出井勝,恩田秀賢,石之神小職
脳卒中の外科 32(3), 172-178, 2004-05-31
… Management of hyperperfusion comprised strict control of the systemic blood pressure and barbiturate therapy. …
NAID 110003739612